.png){kind=icon}
.png){kind=icon}
Return
Economic evaluation of adjuvant chemotherapy for non-metastatic sarcoma using the real-world data from the French nationwide DEEPSARC study
.png){kind=icon}
OA
AI
L
M
S
D
C
A
E
C
H
F
F
A
N
F
A
S
P
E
V
M
G
M
C
G
A
E
N
N
N
J
DOI：10.1080/13696998.2026.2689294.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
The efficacy of adjuvant chemotherapy (AC) in improving survival for patients with sarcoma is debated. We performed a cost-effectiveness analysis (CEA) comparing AC vs. no AC for non-metastatic sarcoma based on the nationwide retrospective study DEEPSARC.
The CEA was carried out over a 1-, 3-, and five-year horizon, using data from the French NETSARC+ database linked to the French national health data system (SNDS).
There was no age limit and no specific histological type selection in the reference case analysis. Costs (expressed in 2021 EUR) were provided by the SNDS from the French national health insurance perspective. Incremental cost effectiveness ratios (ICER) were expressed in cost per life-year gained (LYG). Propensity score analysis with 1:1 matching was undertaken. Sensitivity and subgroup analyses were performed.
Of the 33,548 patients from the French NETSARC+ database, 24,539 were linked to the SNDS. A total of 14,808 patients diagnosed between 2012 and 2017 were included in the reference case analysis with 2,784 patients after propensity score matching. Mean costs (SD) [95% CI] differences per patient between AC and no AC were €12,826 (36,758) [10,883–14,719], €15,706 (49,849) [13,330–18,383], and €16,841 (56,060) [13,590–19,657] at 1, 3, and 5 years, respectively. Mean overall survival differences per patient (in years) were 0.0066 (0.1685) [−0.0021 to 0.0157], −0.0728 (0.9336) [−0.1237 to −0.0229], and −0.1204 (1.3595) [−0.1926 to −0.0475] at 1, 3, and 5 years, respectively. ICER was €1,934,511 [−11,767,351–15,829,959] per LYG at 1 year. AC lagged behind at 3 and 5 years.
In the reference case analysis, AC outperformed its use in terms of outcomes at 1 year, but a high level of willingness to pay would be required for AC to be cost-effective. At 3 and 5 years, AC was deemed to be not cost-effective for patients with non-metastatic sarcoma.
Keywords:
Adjuvant chemotherapy
cancer
cost-effectiveness analysis
Health Data Hub
observational study
sarcoma
SNDS
soft tissue sarcoma
I18
D61
Journal
IF:
3
Papers:
347
Citations:
3.6K
Organization
C
Cited Papers